Nanopublication

< Home

ID

http://purl.org/np/RAxEZRWWgJRYVRUC_d4ezmYcHkw2KATzgdIgSBj1P8d6k

Formats

.trig | .trig.txt | .jelly | .jelly.txt

Content

@prefix orcid: <https://orcid.org/> .
@prefix this: <http://purl.org/np/RAxEZRWWgJRYVRUC_d4ezmYcHkw2KATzgdIgSBj1P8d6k> .
@prefix sub: <http://purl.org/np/RAxEZRWWgJRYVRUC_d4ezmYcHkw2KATzgdIgSBj1P8d6k#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix ns2: <http://twoc-nlp-database-server-1:8555/solr/triples/select?fl=TRIPLE_UID,%20CORD_UID,%20SUBJECT,%20PREDICATE,%20WORDNET_SEMREL,%20%20OBJECT,%20PRED_POSITION,%20SUBJECT_CUIS,%20OBJECT_CUIS,%20UMLS_SEMREL,%20PRED_POSITION,%20PREDICATE-LEMMA&q=CORD_UID:d2wau7rl&rows=> .
@prefix ns1: <http://wordnet-rdf.princeton.edu/lemma/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix ns3: <http://twoc-nlp-database-server-1:8555/solr/triples/select?q=TRIPLE_UID:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo .
}

sub:assertion {
  <https://uts.nlm.nih.gov/uts/umls/concept/C0231491> ns1:reduce <https://uts.nlm.nih.gov/uts/umls/concept/C0520909> .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-12-16T19:44:19.297900"^^xsd:dateTime;
    prov:wasGeneratedBy "S&T TWOC project version 2" .
  
  sub:version prov:value "2"^^xsd:integer .
  
  rdf:OBJECT rdfs:label "the incidence of PONV ( 3.05 % , 22/721 )" .
  
  rdf:OBJECT-POSITION rdfs:label "16"^^xsd:integer .
  
  rdf:PREDICATE rdfs:label "reduced" .
  
  rdf:PREDICATE-POSITION rdfs:label "[67]" .
  
  rdf:SUBJECT rdfs:label "Results dexamethasone and 5-HT3 antagonist combination" .
  
  rdf:SUBJECT-POSITION rdfs:label "32"^^xsd:integer .
  
  rdfs:ABSTRACT-UID ns2:50 "d2wau7rl" .
  
  rdfs:SENTENCE rdfs:label "Results dexamethasone and 5-HT3 antagonist combination effectively reduced the incidence of PONV (3.05%, 22/721), and the patients who experienced PONV had statistically prolonged phase II recovery time as compared those who did not (P) = 0.006)." .
  
  rdfs:TRIPLE-UID ns3:d2wau7rl-TRIPLE-ABSTRACT-5 "d2wau7rl-TRIPLE-ABSTRACT-5" .
  
  <https://uts.nlm.nih.gov/uts/umls/concept/C0231491> rdfs:label "antagonist" .
  
  <https://uts.nlm.nih.gov/uts/umls/concept/C0520909> rdfs:label "ponv" .
}

sub:pubInfo {
  sub:assertion prov:wasDerivedFrom <https://doi.org/10.4103/ija.ija_16_20> .
  
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB";
    npx:hasSignature "IC0bvAVXtUmAnAX49MOQwsZHxet/iZ0gvb7M3n/vYzmX2943438mDwuOhVv6fnqO4y+jMKMEbyBXP6fvUei2zW3OVf2x395hbCr8ttVcdprdkzA156slbSjPz4W/i4TLI582EUdJebB9ug8JtIlI/wtz+cr0u70yuVC67Lf0obg=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-12-16T19:44:19.297900"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}